

YOU ARE CORDIALLY INVITED TO ATTEND A SPEAKER PROGRAM

REZLIDHIA[®]
(olutasidenib) 150 mg capsules

REZLIDHIA Induces Durable Complete Remissions In Adult Patients With Relapsed/Refractory mIDH1 AML

INDICATION

REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Presented by:

Praneeth Baratam, MD
Director of Leukemia
MUSC Hollings Cancer Center
Charleston, South Carolina

Host Information:

Angela Cieplevicz
acieplevicz@rigel.com
(312) 671-2908

When:

Tuesday, July 09, 2024
05:30 PM EST

Program Location:

Noble Fare
321 Jefferson Street, Savannah, Georgia 31401-4228

RSVP:

PLEASE REGISTER BY VISITING US ONLINE AT:

<https://rsvp.rigelsp.cm-go.com/home/index/RI-08438>

In accordance with the PhRMA Code of Ethics, no alcohol will be provided at this educational program.

This program is intended for healthcare professionals only. You may receive certain transfers of value and/or in-kind benefits from Rigel Pharmaceuticals Inc. in connection with your attendance at this program. Rigel Pharmaceuticals Inc. will report such transfers of value and/or in-kind benefits in accordance with Federal and/or State requirements. Minnesota, New Jersey, Vermont, and Federal Entities (e.g., VA, DoD) have restrictions on receiving certain transfers of value and/or in-kind benefits at industry-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Rigel Pharmaceuticals Inc. policies may restrict you from consuming any portion of the meal or from receiving any other in-kind benefit in connection with the program, and may opt-out accordingly. This program and program speakers are sponsored by Rigel Pharmaceuticals, Inc. Please refer to the program host regarding any questions or concerns.

SELECT IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME

Differentiation syndrome, which can be fatal, can occur with REZLIDHIA treatment. Symptoms may include dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain. If differentiation syndrome is suspected, withhold REZLIDHIA and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution.

Please see additional Important Safety Information on the reverse side

REZLIDHIA[®]
(olutasidenib) 150 mg capsules

© 2024 Rigel Pharmaceuticals, Inc. All Rights Reserved.
REZLIDHIA is a registered trademark of Rigel Pharmaceuticals, Inc.
611 Gateway Blvd, Suite 900, South San Francisco, CA 94080

rigel[®]

REZ_AML-23149